$CELG (Celgene Corporation)

$CELG {{ '2016-01-11T16:49:07+0000' | timeago}} • Announcement

$CELG said it expects 2016 net product sales of about $10.5-11Bil, a 17% rise YoverY based on midpoint of range. The negative impact of foreign exchange on net product sales is expected to be about $120MM in 2016. Adjusted EPS is projected to be $5.50-5.70, a 19% increase YoverY, and GAAP EPS is anticipated to be $4.26-4.64.

$CELG {{ '2017-07-27T19:16:33+0000' | timeago}} • Announcement

For FY17, $CELG cut down its GAAP EPS outlook to $5.36-5.62 from its prior estimate of $5.95-6.29. However, Celgene lifted its non-GAAP EPS outlook to $7.25-7.35 from its previous estimate of $7.15-7.30. The company didn't alter its previous revenue outlook of $13.0-13.4Bil.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$CELG {{ '2017-07-25T20:43:29+0000' | timeago}} • Announcement

$CELG, which is set to release its earnings results on July 27, settles a lawsuit filed by Beverly Brown, a former saleswoman of the drugmaker, by paying a total of $280MM. The lawsuit claimed that Celgene used illegal marketing tactics to promote its cancer drugs Thalomid and Revlimid among doctors.

$CELG {{ '2017-07-06T14:11:20+0000' | timeago}} • Announcement

Upon closing of $CELG/$BGNE transaction, which is expected during 3Q17, BeiGene to receive upfront license fees of $263MM and $150MM in equity investment. BeiGene will also be eligible to receive up to $980MM in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317, a drug used to treat cancers.

$CELG {{ '2017-07-06T14:08:05+0000' | timeago}} • Announcement

$CELG enters into a collaborative agreement with biopharma company $BGNE to treat tumor cancers. Celgene will acquire 32.7MM or 5.9% of BeiGene's ordinary shares at $4.58 per share. BeiGene to acquire Celgene's commercial operations in China. BeiGene will also license and assume commercial responsibility for Celgene's approved therapies in China.

$CELG {{ '2017-06-19T12:38:44+0000' | timeago}} • Announcement

Pharma firm $CELG said it would present data from various clinical studies evaluating its  investigational agents for the treatment of blood cancer, at the European Hematology Association’s annual meeting to be held in Madrid, Spain, from June 22 to 25. The data will support the role of Celgene’s therapies as the foundation of myeloma research.

$CELG {{ '2017-06-19T10:48:16+0000' | timeago}} • Announcement

$CELG announced results from interim analysis of Magnify, a phase 3b, randomized, open-label, multicenter study of Revlimid (lenalidomide) plus rituximab combination therapy in patients with relapsed or refractory marginal zone lymphoma (MZL). Lymphoma a group of blood cell tumors that develop from lymphocytes (a type of white blood cell).

$CELG {{ '2017-06-14T11:57:50+0000' | timeago}} • Announcement

Celgene International Sarl, a subsidiary of $CELG, announced results from the phase 2a SLE-001 trial evaluating CC-220, its investigational, oral immunomodulatory compound. A trend toward greater improvement with CC-220 treatment compared with placebo in multiple measures of disease activity was observed in patients with lupus.

$CELG {{ '2017-06-06T17:22:32+0000' | timeago}} • Announcement

Pharma companies $CELG and $AGIO said their phase-1 study on leukemia drug Idhifa in patients with relapsed or refractory acute myeloid leukemia and isocitrate dehydrogenase-2 mutation demonstrated an overall response rate of 40.3%. The outcome reinforces the potential for Idhifa as a first-in-class therapy for such patients.

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$CELG {{ '2017-05-22T12:25:38+0000' | timeago}} • Announcement

$CELG announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR).

$CELG {{ '2017-04-27T14:45:31+0000' | timeago}} • Webcast

$CELG's pipeline includes around 14 unique molecules that are in late-stage development or in proof-of-concept stage development between 2017-2022 and provide opportunity for diversification. $CELG forecasts about $1Bil in revenue from about 10 of these molecules with the other 4 being multi-billion dollar opportunities.

$CELG {{ '2017-04-27T14:30:05+0000' | timeago}} • Webcast

During 1Q17, $CELG saw contraction in the market for OTEZLA, as it saw increased gross-to-net adjustments related to contracts. This gives the company access to up to 100MM insured lives going forward. $CELG also saw minimal drawdown on the inventory. OTEZLA continues to grow market share and gained more than 40% of new patients.

$CELG {{ '2017-04-27T12:17:26+0000' | timeago}} • Infographic

$CELG Celgene Corporation Earnings AlphaGraphics: Q1 2017 Highlights

$CELG {{ '2017-04-27T12:06:27+0000' | timeago}} • Announcement

For 2017, $CELG expects total revenue to be $13-13.4Bil. Diluted EPS is expected to be $5.95-6.29 while adjusted diluted EPS is expected to be $7.15-7.30. Operating margin is expected to be approx. 46% while adjusted operating margin is expected to be 57%.

$CELG {{ '2017-04-27T12:02:21+0000' | timeago}} • Announcement

$CELG reported an increase in 1Q17 earnings helped by higher revenues. Net income was $941MM or $1.16 per share compared to $801MM or $0.99 per share in 1Q16. Total revenue was $2.96Bil, an 18% increase compared to 1Q16. Net product sales were $2.95Bil, up 18% from 1Q16.

$CELG {{ '2017-02-24T13:15:42+0000' | timeago}} • Announcement

$CELG said its President and COO Jacqualyn Fouse has decided to retire from the company effective June 30, 2017. She will continue to serve as President and COO until April 1, and through June 30, she will serve as a strategic advisor to the management team. Jackie will not stand for reelection to BoD at the upcoming Annual Meeting in June.

$CELG {{ '2017-02-24T13:14:32+0000' | timeago}} • Announcement

$CELG said President and COO Jacqualyn Fouse has decided to retire from the company effective June 30, 2017. The company promoted Scott Smith to President and COO, effective April 1, 2017, and the promotion of Terrie Curran to President, Global Inflammation & Immunology (I&I) Franchise, effective April 1, 2017.

$CELG {{ '2017-01-26T17:15:18+0000' | timeago}} • Announcement

$CELG agreed to buy privately-held Delinia, Inc., a biotechnology company developing novel therapeutics for autoimmune diseases. $CELG will make an initial payment of $300MM. Delinia shareholders will be eligible to receive up to an additional $475MM in contingent payments. The transaction is expected to close in 1Q17.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
VCEL (Vericel Corporation)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ATHX (Athersys, Inc.)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm

AlphaGraphics you may like